Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shingles may trigger dementia: study probes hidden danger

NCT ID NCT06903078

Knowledge-focused Sponsor: Center for Clinical Studies, Texas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study looks at whether people with shingles (herpes zoster) have a higher risk of vascular dementia—memory loss from reduced blood flow to the brain. Researchers will analyze tiny particles called exosomes in blood samples from 375 participants over 12 months. No treatment is given; the goal is to understand the connection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal biological links between shingles and vascular dementia, pointing toward future prevention strategies.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not lead to direct medical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 375 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Each year, 50 control subjects and 25 zoster individuals will be recruited to provide blood samples for this study, as well as clinical and laboratory information. This study will recruit individuals reflective of the United States demographics: 58% white (non-Hispanic), 19% Hispanic, 12% Black/African American, 6% Asian, and 5% two or more races. Houston is the fourth most populous city in the United States and has a demographic breakdown and population pool conducive to reflect the United States population. We will aim to recruit the following annually for years 1-5: (1) of the 50 control subjects, 29 White (non-Hispanic), 10 Hispanic, 6 Black/African American, 3 Asian, 2 Other (two or more), and (2) of the 25 control subjects, 14 White (non-Hispanic), 5 Hispanic, 3 Black/African American, 2 Asian, 1 Other (two or more). Within each ethnic group, half will be women and half men.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: At the Screening Visit (Visit 1/Day 1), all participants must meet all the following criteria in order to be considered for participation in the study: 1. Be a male or female ≥ 18 years of age. 2. Present to clinic for routine dermatologic evaluation with or without rash. 3. Are willing and able to complete study visits and procedures, and able to effectively communicate with the investigator and other study personnel. 4. Have adequate venous access and are willing to undergo venipuncture for blood draws. 5. Able to provide written informed consent prior to any study procedures. Additional inclusion criteria for Herpes zoster (HZ) participants, 6. Present with acute, vesicle-stage HZ that has not been treated with antiviral therapies 7. Are willing and have reliable transportation to complete additional follow-up visits at 7 days, 1 month, 3 months, 6 months, and 12 months after initial visit for acute HZ. Exclusion Criteria: At the Screening Visit (Visit 1/Day 1), participants meeting any of the following criteria will be excluded from participation in the study: 1. Female individuals who are pregnant or breast-feeding. 2. Receiving systemic or topical antivirals for varicella zoster virus (VZV). 3. Sensitivity or allergy to systemic or topical antiviral medications for HZ. 4. History of diagnosed HZ within the last 8 years. 5. Received a HZ vaccine (e.g., Zostavax®/Shingrix®) within the last 8 years. 6. Received any vaccinations within the last 3 months. 7. Currently taking immunosuppressive therapies, including medications and radiation. 8. Currently taking any anticoagulants. 9. History of any coagulation disorder(s). 10. History of end-stage renal disease or uremia. 11. History of end-stage liver disease. 12. History of HIV. 13. Have had a COVID-19 infection in last 3 months. 14. Any history of non-skin cancers within the last 3 months. 15. History of serious infection requiring hospitalization in the last 3 months. 16. Prior history of cardiovascular accident or myocardial infarction within the last 12 months. 17. Prior cerebrovascular accident in the past 12 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Herpes zoster (HZ) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

herpes zoster vascular dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Herpes zoster (HZ) Vascular dementia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    2 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Center for Clinical Studies, LTD. LLP

    RECRUITING

    Houston, Texas, 77004, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • Center for Clinical Studies, LTD. LLP

    RECRUITING

    Webster, Texas, 77598, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.